Intravesical oncolytic viral therapy using attenuated, replication‐competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model
- 5 March 2001
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 15 (7) , 1306-1308
- https://doi.org/10.1096/fj.00-0533fje
Abstract
No abstract availableFunding Information
- National Institutes of Health (RO1CA76416-01, RO1CA/DK80982-01, RO1CA72632-01A1)
- American Cancer Society (MBC-99366)
This publication has 32 references indexed in Scilit:
- Neoadjuvant cisplatin,methotrexate,and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trialThe Lancet, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Fortnightly review: Bladder cancerBMJ, 1998
- Tumour progression and survival in patients with T1G3 bladder tumours: 15‐year outcomeBritish Journal of Urology, 1997
- Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1European Journal Of Cancer, 1997
- Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer.Journal of Clinical Oncology, 1997
- Apparent Failure of Current Intravesical Chemotherapy Prophylaxis to Influence the Long-Term Course of Superficial Transitional Cell Carcinoma of the BladderJournal of Urology, 1995
- BCG in Perspective: Advances in the Treatment of Superficial Bladder CancerEuropean Urology, 1995
- BCG in Superficial Bladder Cancer: A Review of Phase III European TrialsEuropean Urology, 1992
- Experience with intravesical bacillus calmette-guèrin therapy of superficial bladder tumorsUrology, 1985